Your prediction
ALS Ltd Stock
There is an upward development for ALS Ltd compared to yesterday, with an increase of €0.30 (2.540%).
Pros and Cons of ALS Ltd in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of ALS Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ALS Ltd | 2.540% | -0.820% | 4.310% | 31.522% | 35.196% | 53.165% | 96.748% |
| Seek Ltd | -0.780% | -5.185% | -7.914% | -14.094% | -5.882% | -9.220% | -22.424% |
| Downer EDI Ltd | 0.450% | 1.376% | 3.756% | 36.420% | 41.667% | 84.167% | 37.267% |
| Insperity Inc. | 5.190% | 7.285% | 14.894% | -58.987% | -55.310% | -70.811% | -53.381% |
News
North American Niobium and Critical Minerals Corp. Completes Phase 1 Fall Prospecting Program; Carbonatite and Pegmatite Targets Identified Across Québec Properties
- Completion of Fall 2025 Prospecting Program Across Seigneurie, Bardy, Blanchette and Sabot Properties
- Carbonatite Boulders and Pegmatite Zones Identified
- 262
Electromed Posts 17% Gain in Fiscal Q4
Electromed (NYSEMKT:ELMD), a medical device company specializing in airway clearance therapy, reported record financial results for the quarter and fiscal year ended August 26, 2025. The company’s
Clene Posts 70% Revenue Drop in Q2
Clene (NASDAQ:CLNN), a clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases, released its second-quarter 2025 earnings on August 14, 2025. The most important